Metastatic Cancer
622
82
126
302
Key Insights
Highlights
Success Rate
78% trial completion
Published Results
103 trials with published results (17%)
Research Maturity
302 completed trials (49% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.5%
84 terminated out of 622 trials
78.2%
-8.3% vs benchmark
9%
55 trials in Phase 3/4
34%
103 of 302 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 302 completed trials
Clinical Trials (622)
Harvesting Cells for Experimental Cancer Treatments
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
PRE-ISPY Phase I/II Oncology Platform Program
IL-15 Enhanced NK Cell Therapy for Solid Tumors
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
SLV-154 Treatment of Advanced Cancers
A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)
Prospective Validation of a Points Score System Predicting 30-day Survival
Optimizing Y90 Therapy for Radiation Lobectomy
Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas
COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
Trial Comparing LATTICE Radiotherapy vs Moderately Dose-escalated Palliative Radiation for Patients With Metastases.
Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer